Roy Fox

4.5k total citations · 1 hit paper
103 papers, 3.5k citations indexed

About

Roy Fox is a scholar working on Immunology, Epidemiology and Hepatology. According to data from OpenAlex, Roy Fox has authored 103 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Immunology, 20 papers in Epidemiology and 14 papers in Hepatology. Recurrent topics in Roy Fox's work include Macrophage Migration Inhibitory Factor (15 papers), Nuclear physics research studies (10 papers) and Fibromyalgia and Chronic Fatigue Syndrome Research (9 papers). Roy Fox is often cited by papers focused on Macrophage Migration Inhibitory Factor (15 papers), Nuclear physics research studies (10 papers) and Fibromyalgia and Chronic Fatigue Syndrome Research (9 papers). Roy Fox collaborates with scholars based in United Kingdom, Canada and United States. Roy Fox's co-authors include F. J. Dudley, S. Sherlock, Summyah Niazi, Paul Stolee, B. Lynn Beattie, Kenneth Rockwood, Deirdre A. Robertson, Sheila Sherlock, David B. Hogan and Peter J. Scheuer and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

Roy Fox

100 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CELLULAR IMMUNITY AND HEPATITIS-ASSOCIATED, AUSTRALIA ANTIGEN LIVER DISEASE

1972 383 citations F. J. Dudley, Roy Fox et al. profile →

Peers

Countries citing papers authored by Roy Fox

Since Specialization

Citations

This map shows the geographic impact of Roy Fox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roy Fox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roy Fox more than expected).

Fields of papers citing papers by Roy Fox

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roy Fox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roy Fox. The network helps show where Roy Fox may publish in the future.

Co-authorship network of co-authors of Roy Fox

This figure shows the co-authorship network connecting the top 25 collaborators of Roy Fox. A scholar is included among the top collaborators of Roy Fox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roy Fox. Roy Fox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo 2024 ·Journal of Cystic Fibrosis ·Henry Danahay, Clive McCarthy, (unknown), Roy Fox, (unknown), Sarah Lilley, Juan Sabater, Matthias Salathé, Nathalie Baumlin, Stephen P. Collingwood, Martin Gosling	2
2	Niclosamide does not modulate airway epithelial function through blocking of the calcium activated chloride channel, TMEM16A 2023 ·Frontiers in Pharmacology ·Henry Danahay, Sarah Lilley, (unknown), (unknown), Roy Fox, Martin Gosling	11
3	Characterisation of pomegranate juice polyphenols identifies oenothein B as an endothelium-dependent vasodilator and regulator of endothelial function that enhances actions of oligomeric procyanidins 2023 ·European Heart Journal ·Roger Corder, Noorafza Q. Khan, Sarah Lilley, Roy Fox, J. W. TYLER, (unknown), Paul Caton, William Mullen, (unknown), Amrita Ahluwalia, Alan Crozier, (unknown)	0
4	TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis 2020 ·American Journal of Respiratory and Critical Care Medicine ·Henry Danahay, Sarah Lilley, Roy Fox, (unknown), Juan Sabater, Brian Button, Clive McCarthy, Stephen P. Collingwood, Martin Gosling	65
5	WS03-6 TMEM16A potentiators: a new therapeutic opportunity for treating Cystic Fibrosis-Related Lung Disease 2019 ·Journal of Cystic Fibrosis ·Henry Danahay, Sarah Lilley, (unknown), Roy Fox, Brenda Button, Martin Gosling	3
6	Imatinib Attenuates Hypoxia-induced Pulmonary Arterial Hypertension Pathology via Reduction in 5-Hydroxytryptamine through Inhibition of Tryptophan Hydroxylase 1 Expression 2013 ·American Journal of Respiratory and Critical Care Medicine ·Loredana Ciuclan, Martin Hussey, Victoria J. Burton, Robert B. Good, Nicholas Duggan, (unknown), Peter Lloyd Jones, Roy Fox, Ieuan Clay, Olivier Bonneau, Irena Konstantinova, Andrew C. Pearce, David J. Rowlands, Gábor Járai, John Westwick, Margaret R. MacLean, Matthew J. Thomas	55
7	An evaluation of SNOMED CT® in the domain of complex chronic conditions 2010 ·International Journal of Integrated Care ·Tara Sampalli, Michael Shepherd, Jack Duffy, Roy Fox	9
8	The Impact of A Multidisciplinary, Holistic Approach to Management of Patients Diagnosed with Multiple Chemical Sensitivity on Health Care Utilization Costs: An Observational Study 2007 ·The Journal of Alternative and Complementary Medicine ·Roy Fox, Michel R. Joffres, Tara Sampalli, Jill Casey	9
9	Rituximab for adolescents with haemophilia and high titre inhibitors 2006 ·Haemophilia ·Roy Fox, Ellis J. Neufeld, Carolyn M. Bennett	39
10	Essential role for the p110δ phosphoinositide 3-kinase in the allergic response 2004 ·Nature ·Khaled Ali, Antonio Bilancio, Matthew J. Thomas, Wayne Pearce, Alasdair M. Gilfillan, Christine Tkaczyk, (unknown), Alexander Gray, June Giddings, Emma Peskett, Roy Fox, Ian Bruce, Christoph Walker, (unknown), Klaus Okkenhaug, Peter M. Finan, Bart Vanhaesebroeck	332
11	In Vitro and In Situ Permeability of a 'Second Generation' Hydroxypyridinone Oral Iron Chelator: Correlation with Physico-Chemical Properties and Oral Activity 1999 ·Pharmaceutical Research ·(unknown), Roy Fox, Bernard Faller, Hanspeter Nick, Yi Jin, (unknown), Yulia Hirschberg, Rebecca L. Oberle, (unknown)	13
12	Caco-2 Cell Permeability of a New (Hydroxybenzyl)ethylenediamine Oral Iron Chelator: Correlation with Physicochemical Properties and Oral Activity 1998 ·Journal of Pharmaceutical Sciences ·(unknown), Brian Tomlinson, Roy Fox, Bernard Faller, (unknown), (unknown)	13
13	Safety profile of ciprofloxacin during long-term therapy for pulmonary tuberculosis 1993 ·Journal of Antimicrobial Chemotherapy ·N. Kennedy, Roy Fox, L. Uiso, F.I. Ngowi, Stephen H. Gillespie	18
14	Treatment Recommendations for Respiratory Tract Infections Associated with Aging 1993 ·Drugs & Aging ·Roy Fox	14
15	A Prospective Controlled Trial of a Geriatric Consultation Team in an Acute-care Hospital 1990 ·Age and Ageing ·David B. Hogan, Roy Fox	81
16	Gynecologic Sepsis as a Cause of Covert Infection in Old Age 1983 ·Journal of the American Geriatrics Society ·Michael A. Horan, John Puxty, Roy Fox	3
17	The White Nails of Old Age 1982 ·Journal of the American Geriatrics Society ·Michael A. Horan, John Puxty, Roy Fox	22
18	Macrophage Receptors for Migration Inhibitory Factor (MIF), Migration Stimulatory Factor (MSF), and Agglutinating Factor 1974 ·The Journal of Immunology ·Roy Fox, Douglas S. Gregory, Joseph D. Feldman	49
19	The serum concentration of the third component of complement β _1C /β _1A in liver disease 1971 ·Gut ·Roy Fox, F. J. Dudley, S Sherlock	39
20	Hepatitis-associated Antigen and Antibody in Haemodialysis Patients and Staff 1970 ·BMJ ·(unknown), Roy Fox, Rosemarie A. Baillod, Summyah Niazi, Sheila Sherlock, J F Moorhead	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact